Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq: INSM) has announced the granting of inducement awards to 52 new employees in accordance with NASDAQ Listing Rule 5635(c)(4). The awards, approved by Insmed's Compensation Committee, were made as a material inducement to each employee's entry into employment with the Company.
On October 1, 2024, the new employees received options to purchase an aggregate of 106,160 shares of Insmed common stock at an exercise price of $72.88 per share, which was the closing trading price on the Nasdaq Global Select Market on the date of grant. The options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first anniversary and 12.5% vesting every six months thereafter through the fourth anniversary, subject to continued service with Insmed.
Insmed Incorporated (Nasdaq: INSM) ha annunciato l'assegnazione di premi di incentivazione a 52 nuovi dipendenti in conformità con la Regola di Quotazione NASDAQ 5635(c)(4). I premi, approvati dal Comitato Compensi di Insmed, sono stati concessi come incentivo sostanziale per l'ingresso di ciascun dipendente nell'azienda.
Il 1 ottobre 2024, i nuovi dipendenti hanno ricevuto opzioni per acquistare un totale di 106.160 azioni ordinarie di Insmed a un prezzo di esercizio di $72,88 per azione, che era il prezzo di chiusura sul Nasdaq Global Select Market alla data di assegnazione. Le opzioni hanno un termine di 10 anni e un programma di maturazione di quattro anni, con il 25% che matura al primo anniversario e il 12,5% ogni sei mesi successivamente fino al quarto anniversario, soggetto a un servizio continuato con Insmed.
Insmed Incorporated (Nasdaq: INSM) ha anunciado la concesión de premios de incentivo a 52 nuevos empleados de acuerdo con la Regla de Cotización NASDAQ 5635(c)(4). Los premios, aprobados por el Comité de Compensación de Insmed, se otorgaron como un incentivo material para cada empleado al ingresar a la compañía.
El 1 de octubre de 2024, los nuevos empleados recibieron opciones para comprar un total de 106,160 acciones ordinarias de Insmed a un precio de ejercicio de $72.88 por acción, que era el precio de cierre en el Nasdaq Global Select Market en la fecha de concesión. Las opciones tienen un plazo de 10 años y un programa de adquisición de cuatro años, con el 25% que se adquiere en el primer aniversario y el 12.5% que se adquiere cada seis meses a partir de entonces hasta el cuarto aniversario, sujeto a la continuidad del servicio con Insmed.
Insmed Incorporated (Nasdaq: INSM)은 NASDAQ 상장 규칙 5635(c)(4)에 따라 52명의 신규 직원에게 유인 보상을 부여한다고 발표했습니다. 이 보상은 Insmed의 보상 위원회에서 승인되었으며, 각 직원이 회사에 입사하는 데 있어 중요한 유인이 되었습니다.
2024년 10월 1일, 신규 직원들은 Insmed 보통주 106,160주를 주당 $72.88의 행사 가격으로 구매할 수 있는 옵션을 받았습니다. 이 가격은 부여일에 Nasdaq Global Select Market의 종가였습니다. 이 옵션은 10년의 기간과 4년의 가속 기간을 가지며, 첫 번째 기념일에 25%가 성숙되고 이후부터는 6개월마다 12.5%씩 네 번째 기념일까지 성숙됩니다. Insmed에서 지속적인 서비스가 필요합니다.
Insmed Incorporated (Nasdaq: INSM) a annoncé l'octroi de récompenses d'incitation à 52 nouveaux employés conformément à la Règle d'Inscription NASDAQ 5635(c)(4). Les récompenses, approuvées par le Comité de Rémunération d'Insmed, ont été accordées comme un incitatif matériel à l'entrée de chaque employé dans l'entreprise.
Le 1er octobre 2024, les nouveaux employés ont reçu des options d'achat d'un total de 106.160 actions ordinaires d'Insmed à un prix d'exercice de $72,88 par action, qui était le prix de clôture sur le Nasdaq Global Select Market à la date d'octroi. Les options ont une durée de 10 ans et un plan d'acquisition de quatre ans, avec 25% d'acquisition à l'anniversaire de la première année et 12,5% d'acquisition tous les six mois par la suite jusqu'à la quatrième année, sous réserve d'un service continu avec Insmed.
Insmed Incorporated (Nasdaq: INSM) hat die Gewährung von Anreizprämien an 52 neue Mitarbeiter gemäß der NASDAQ-Listing-Regel 5635(c)(4) bekannt gegeben. Die Prämien, die vom Vergütungsausschuss von Insmed genehmigt wurden, dienten als wesentlicher Anreiz für den Eintritt eines jeden Mitarbeiters in die Gesellschaft.
Am 1. Oktober 2024 erhielten die neuen Mitarbeiter Optionen zum Kauf von insgesamt 106.160 Aktien der Insmed-Stammaktien zu einem Ausübungspreis von $72,88 pro Aktie, was dem Schlusspreis am Nasdaq Global Select Market zum Zeitpunkt der Gewährung entsprach. Die Optionen haben eine Laufzeit von 10 Jahren und einen Vesting-Zeitplan von vier Jahren, wobei 25% am ersten Jahrestag und 12,5% alle sechs Monate danach bis zum vierten Jahrestag fällig werden, vorbehaltlich einer fortgesetzten Dienstleistung bei Insmed.
- Granted stock options to 52 new employees, potentially attracting and retaining talent
- Options have a 10-year term, providing long-term incentives for employees
- Four-year vesting schedule encourages employee retention
- Potential dilution of existing shareholders due to the issuance of 106,160 new stock options
In connection with the commencement of their employment, the employees received options on October 1, 2024 to purchase an aggregate 106,160 shares of Insmed common stock at an exercise price of
The options have a 10-year term and a four-year vesting schedule, with
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater,
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Media:
Mandy Fahey
Vice President, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302266891.html
SOURCE Insmed Incorporated
FAQ
How many new employees received inducement grants from Insmed (INSM) on October 1, 2024?
What was the exercise price for the stock options granted by Insmed (INSM) on October 1, 2024?
What is the vesting schedule for the stock options granted by Insmed (INSM) to new employees?
How many shares of Insmed (INSM) common stock were included in the aggregate stock options granted on October 1, 2024?
